1-benzyloxy-3-butyn-2-one | 94075-59-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-benzyloxy-3-butyn-2-one
• 英文别名: 1-(benzyloxy)but-3-yn-2-one；1-phenylmethoxybut-3-yn-2-one
• CAS: 94075-59-9
• 化学式: C₁₁H₁₀O₂
• 分子量: 174.199
• InChiKey: PHHKXYZTKLXIGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-benzyloxy-3-butyn-2-one 生成 (S)-1-苄氧基-3-丁炔-2-醇
  参考文献：
  名称：

  VIGNERON, J. P.;MERIC, R.;LARCHEVEQUE, M.;DEBAL, A.;LALLEMAND, J. Y.;KUNE+, TETRAHEDRON, 1984, 40, N 18, 3521-3529

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(benzyloxy)but-3-yn-2-ol 在 chromium(VI) oxide 、 硫酸 作用下， 以74%的产率得到1-benzyloxy-3-butyn-2-one
  参考文献：
  名称：

  L'eldanolide，信息素DES glandes alaires德拉pyrale德拉CANNEà苏克雷，eldana saccharina（WLK）：结构等SYNTHESE德SES德塞夫勒énantiomères

  摘要：

  描述了雄性非洲甘蔗Bor的翅腺信息素-艾考多奈的分离和结构测定，该药为埃尔达纳糖精（Wlk。）。通过将天然信息素与两种合成对映异构体的CD光谱进行比较，将绝对构型确定为（3S，4R）。

  DOI：

  10.1016/s0040-4020(01)91504-2

文献信息

• Studies on Thiopeptide Antibiotics: Synthesis of an Oxazole-Thiazole-Pyridine Fragment related to Promothiocin A
  作者：Christopher J. Moody、Mark C. Bagley

  DOI：10.1055/s-1998-1670

  日期：1998.4

  Promothiocin A 1, isolated from Streptomyces sp. SF2741, is a member of the thiopeptide family of antibiotics. These antibiotics, which inhibit protein synthesis in bacteria and induce the expression of various genes (of unknown function), are characterised by their complex structure in which an array of heterocyclic rings is incorporated into a macrocyclic peptide framework. Despite the fascinating biological activity of the thiopeptide antibiotics, very little synthetic work has been carried out to date, although the synthesis of the pyridine fragments of the micrococcins, sulfomycin and nosiheptide has been addressed recently, as has the construction of some related pyridines. In continuation of our interest in the synthesis of heterocyclic natural products, we now report the synthesis of the oxazole-thiazole-pyridine 2, which contains the required functionality for elaboration into promothiocin A 1.

  从链霉菌SF2741中分离得到的普罗莫西辛A 1，属于硫肽类抗生素家族。这类抗生素通过抑制细菌蛋白质合成并诱导多种未知功能基因的表达，其特点在于复杂的结构中，一系列杂环结构被整合到一个大环肽骨架中。尽管硫肽类抗生素具有引人注目的生物活性，但迄今为止，关于其合成的工作非常有限。虽然最近已解决微球菌素、硫霉素和诺西肽的吡啶片段的合成问题，以及一些相关吡啶结构的构建，但整体合成进展仍显不足。继我们对杂环天然产物合成的兴趣之后，我们现在报道了含有呋喃-噻唑-吡啶结构的化合物2的合成，该结构含有进一步合成普罗莫西辛A 1所需的功能基团。
• Small Molecule Inhibitors of KRAS G12C Mutant
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20210122764A1

  公开（公告）日：2021-04-29

  The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W 1 , W 2 , Y, Z, M, L, C y , C z , R 1 , R 2 , R 3 , R 4 , R 2a , R y , R z and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

  该披露提供了Formula (I)的化合物或其药用盐，其中W1、W2、Y、Z、M、L、Cy、Cz、R1、R2、R3、R4、R2a、Ry、Rz以及下标m、n、q和r如本文所述。这些化合物或其药用盐可以抑制Kirsten大鼠肉瘤（KRAS）蛋白的G12C突变体，并有望作为治疗剂具有用途，例如用于治疗癌症。该披露还提供了包含Formula (I)的化合物或其药用盐的药物组合物。该披露还涉及使用这些化合物或其药用盐在癌症的治疗和预防中的方法，以及为此目的制备药物。
• L'eldanolide, phéromone des glandes alaires de la pyrale de la canne à sucre, eldana saccharina (wlk.): structure et synthèse de ses deux énantiomères
  作者：J.P. Vigneron、R. Méric、M. Larchevêque、A. Debal、J.Y. Lallemand、G. Kunesch、P. Zagatti、M. Gallois

  DOI：10.1016/s0040-4020(01)91504-2

  日期：1984.1

  The isolation and structure determination of eldanolide, the wing gland pheromone of the male African Sugar Cane Borer, Eldana saccharina (Wlk.) is described. The absolute configuration was determined as (3S, 4R) by comparison of the CD spectra of the natural pheromone with both synthetic enantiomers.

  描述了雄性非洲甘蔗Bor的翅腺信息素-艾考多奈的分离和结构测定，该药为埃尔达纳糖精（Wlk。）。通过将天然信息素与两种合成对映异构体的CD光谱进行比较，将绝对构型确定为（3S，4R）。
• [EN] COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE<br/>[FR] COMPOSÉS DESTINÉS À CIBLER LA DÉGRADATION DE LA TYROSINE KINASE DE BRUTON
  申请人：BIOGEN MA INC

  公开号：WO2022235945A1

  公开（公告）日：2022-11-10

  This disclosure relates to compounds of Formula (A): BTK— L— DSM (A) or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently attaches BTK to DSM, and BTK is a Btk binding moiety represented by Formula (I) or Formula (II) that is covalently attached to linker L: in which all of the variables are as defined in the application. Compounds or pharmaceutically acceptable salts thereof as described herein are capable of activating the selective ubiqitination of Btk proteins via the ubiquitin-proteasome pathways (UPP) and cause degradation of Btk proteins. The present disclosure also provides methods of treating disorders responsive to modulation of Btk activity and/or degradation of Btk with at least one compound described herein.

  本公开涉及式(A)化合物：BTK-L-DSM(A)或其药学上可接受的盐，其中DSM是降解信号基团，与连接基L共价结合，L是将BTK与DSM共价连接的连接基，而BTK是由式(I)或式(II)表示的结合Btk的基团，其与连接基L共价连接。其中所有变量均如所述申请中定义。如本文所述的化合物或其药学上可接受的盐能够通过泛素-蛋白酶体途径（UPP）激活选择性泛素化Btk蛋白并导致Btk蛋白的降解。本公开还提供了使用至少一种本文所述化合物治疗对Btk活性调节和/或Btk降解具有反应的疾病的方法。
• 10.1021/acs.jmedchem.4c00572
  作者：Ma, Xiaoshen、Sloman, David L.、Duggal, Ruchia、Anderson, Kenneth D.、Ballard, Jeanine E.、Bharathan, Indu、Brynczka, Christopher、Gathiaka, Symon、Henderson, Timothy J.、Lyons, Thomas W.、Miller, Richard、Munsell, Erik V.、Orth, Peter、Otte, Ryan D.、Palani, Anandan、Rankic, Danica A.、Robinson, Michelle R.、Sather, Aaron C.、Solban, Nicolas、Song, Xuelei Sherry、Wen, Xin、Xu, Zangwei、Yang, Yi、Yang, Ruojing、Day, Phil J.、Stoeck, Alexander、Bennett, David Jonathan、Han, Yongxin

  DOI：10.1021/acs.jmedchem.4c00572

  日期：——

  Oncogenic mutations in the RAS gene account for 30% of all human tumors; more than 60% of which present as KRAS mutations at the hotspot codon 12. After decades of intense pursuit, a covalent inhibition strategy has enabled selective targeting of this previously “undruggable” target. Herein, we disclose our journey toward the discovery of MK-1084, an orally bioavailable and low-dose KRASG12C covalent

  RAS基因的致癌突变占所有人类肿瘤的30%；其中超过 60% 表现为热点密码子 12 处的 KRAS 突变。经过数十年的不懈努力，共价抑制策略已经能够选择性靶向这一以前“不可成药”的靶点。在此，我们披露了我们发现 MK-1084 的历程，MK-1084 是一种口服生物可利用的低剂量 KRAS G12C共价抑制剂，目前正在进行 I 期临床试验 (NCT05067283)。我们利用基于结构的药物设计来确定大环核心结构，并利用假设驱动的生物制药特性优化来进一步提高代谢稳定性和耐受性。